TriSalus Life Sciences (TLSIW) Invested Capital (2020 - 2026)

TriSalus Life Sciences has reported Invested Capital for 7 years, with the latest figure at $45.9 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 1817.93% year-over-year to $45.9 million; the trailing twelve-month figure through Mar 2026 stood at $45.9 million (up 1817.93% YoY), and the FY2025 full-year result was -$815000.0, up 78.61% from the prior year.
• Invested Capital for Q1 2026 stood at $45.9 million, up from -$815000.0 in the prior quarter.
• The five-year high for Invested Capital was $45.9 million in Q1 2026, with the low at -$188.4 million in Q2 2023.
• Historically, Invested Capital has averaged -$57.7 million across 5 years, with a median of -$4.0 million in 2024.
• Annual changes were most pronounced in 2022 — Invested Capital plunged 684.82% — and 2026, when it jumped 1817.93%.
• TriSalus Life Sciences' Invested Capital stood at -$174.7 million in 2022, then surged by 84.51% to -$27.1 million in 2023, then surged by 85.92% to -$3.8 million in 2024, then soared by 78.61% to -$815000.0 in 2025, then surged by 5730.18% to $45.9 million in 2026.
• The last three Invested Capital figures came in at $45.9 million (Q1 2026), -$815000.0 (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.